文献速递精神分裂症与精神病性障碍

精神分裂症的分子病理学:现有知识概述与未来研究方向

The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research.
PubMed 文献 · Mol Psychiatry · 2023-03-06

本文综述精神分裂症分子病理学研究现状。遗传学进展可解释超20%的疾病易感性,罕见突变中SETD1A、CUL1、XPO7、GRIA3、GRIN2A和RB1CC1六个基因比值比大于十。基于这些发现构建的疾病模型及患者死后脑组织的转录组和表观基因组分析为分子病理提供了新见解。

要点

  • 考虑所有可分析常见遗传变异可解释超20%的精神分裂症易感性。
  • 六个基因(SETD1A、CUL1、XPO7、GRIA3、GRIN2A、RB1CC1)罕见突变比值比大于十。
  • 疾病模型脑组织及患者死后脑转录组和表观基因组分析揭示分子病理新见解。

核心结论

  • 精神分裂症脑分子病理仍不明确,但遗传学进展显著提升了对疾病风险的解释能力。
  • 基于高效应量遗传变异构建的疾病模型及患者死后脑组织多组学分析为分子病理提供了新方向。

研究设计与样本

  • 综述类文章,汇总遗传学、疾病模型脑组织及患者死后脑组织转录组和表观基因组分析的研究证据。

主要发现

  • 考虑所有可分析常见遗传变异(包括弱或无统计学显著关联的变异)可解释超过20%的精神分裂症易感性。
  • 大规模外显子组测序发现六个基因(SETD1A、CUL1、XPO7、GRIA3、GRIN2A、RB1CC1)罕见突变比值比大于十。
  • 拷贝数变异(CNVs)此前已被发现具有类似大的效应量。
  • 基于上述发现生成的多个疾病模型具有高病因学效度,其脑组织研究及患者死后脑组织转录组和表观基因组分析提供了分子病理新见解。

关键数值与推荐

  • 常见遗传变异整体可解释超过20%的精神分裂症易感性。
  • SETD1A、CUL1、XPO7、GRIA3、GRIN2A和RB1CC1六个基因罕见突变比值比大于十。

临床怎么用

  • 遗传学发现支持基于生物学改变而非操作化标准重新定义精神分裂症的未来方向。
  • 疾病模型和患者死后脑组织多组学分析有助于理解分子病理并推动生物标志物研究。

局限性

  • 精神分裂症脑分子病理仍不明确,现有研究存在局限性。
  • 综述未详细报告具体研究的方法学局限及样本量等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite enormous efforts employing various approaches, the molecular pathology in the schizophrenia brain remains elusive. On the other hand, the knowledge of the association between the disease risk and changes in the DNA sequences, in other words, our understanding of the genetic pathology of schizophrenia, has dramatically improved over the past two decades. As the consequence, now we can explain more than 20% of the liability to schizophrenia by considering all analyzable common genetic variants including those with weak or no statistically significant association. Also, a large-scale exome sequencing study identified single genes whose rare mutations substantially increase the risk for schizophrenia, of which six genes (SETD1A, CUL1, XPO7, GRIA3, GRIN2A, and RB1CC1) showed odds ratios larger than ten. Based on these findings together with the preceding discovery of copy number variants (CNVs) with similarly large effect sizes, multiple disease models with high etiological validity have been generated and analyzed. Studies of the brains of these models, as well as transcriptomic and epigenomic analyses of patient postmortem tissues, have provided new insights into the molecular pathology of schizophrenia. In this review, we overview the current knowledge acquired from these studies, their limitations, and directions for future research that may redefine schizophrenia based on biological alterations in the responsible organ rather than operationalized criteria.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Nakamura T, Takata A. The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research. Mol Psychiatry. 2023. PMID: 36878965. doi:10.1038/s41380-023-02005-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。